Prostate Specific Antigen (PSA) Testing in a General Practice 2009-2019

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2024 Oct 23

PMID 39441509

Authors

Niall Maguire

Andrea Moloney

Krzysztof Fic

Affiliations

Soon will be listed here.

Abstract

Background: Prostate-specific antigen (PSA) testing is not recommended as a population screening measure for prostate cancer. PSA testing is nevertheless widespread and is associated with harm due to false-positive test results, overdiagnosis and economic costs.

Aims: This study sought to document the exposure of patients to PSA testing over a decade in a general medical practice setting.

Methods: Laboratory results for each year were extracted from the clinical record. A chart review was undertaken for cases of prostate cancer.

Results: We report 13,743 PSA results in 3313 men. In any year, 18% of all men and 33% of men aged over 50 years had at least one PSA test. Between 4.8 and 21% of first tests exceeded age normal values depending on age. There were 113 incident cancers in the study interval of which 84 (74%) were screen detected. Mortality was lower in screen-detected than symptomatic cancers.

Conclusions: Men at our practice are significantly exposed to PSA testing. We found evidence of possible overdiagnosis.

References

Schroder F, Hugosson J, Roobol M, Tammela T, Zappa M, Nelen V . Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384(9959):2027-35. PMC: 4427906. DOI: 10.1016/S0140-6736(14)60525-0. View

Pinsky P, Prorok P, Yu K, Kramer B, Black A, Gohagan J . Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2016; 123(4):592-599. PMC: 5725951. DOI: 10.1002/cncr.30474. View

Martin R, Donovan J, Turner E, Metcalfe C, Young G, Walsh E . Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018; 319(9):883-895. PMC: 5885905. DOI: 10.1001/jama.2018.0154. View

Vickers A, OBrien F, Montorsi F, Galvin D, Bratt O, Carlsson S . Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ. 2023; 381:e071082. DOI: 10.1136/bmj-2022-071082. View

Hoffmann T, Del Mar C . Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med. 2014; 175(2):274-86. DOI: 10.1001/jamainternmed.2014.6016. View

Waller J, Osborne K, Wardle J . Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer. 2014; 112(3):562-6. PMC: 4453657. DOI: 10.1038/bjc.2014.643. View

Drummond F, Carsin A, Sharp L, Comber H . Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Ir J Med Sci. 2009; 179(1):43-9. DOI: 10.1007/s11845-009-0376-7. View

Clift A, Coupland C, Hippisley-Cox J . Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017. Br J Gen Pract. 2021; 71(703):e157-e165. PMC: 7805413. DOI: 10.3399/bjgp20X713957. View

Draisma G, Boer R, Otto S, van der Cruijsen I, Damhuis R, Schroder F . Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95(12):868-78. DOI: 10.1093/jnci/95.12.868. View

10.

Pill R, French J, Harding K, Stott N . Invitation to attend a health check in a general practice setting: comparison of attenders and non-attenders. J R Coll Gen Pract. 1988; 38(307):53-6. PMC: 1711284. View

11.

Collins C, Homeniuk R . How many general practice consultations occur in Ireland annually? Cross-sectional data from a survey of general practices. BMC Fam Pract. 2021; 22(1):40. PMC: 7896162. DOI: 10.1186/s12875-021-01377-0. View

12.

Rao K, Liang S, Cardamone M, Joshu C, Marmen K, Bhavsar N . Cost implications of PSA screening differ by age. BMC Urol. 2018; 18(1):38. PMC: 5944051. DOI: 10.1186/s12894-018-0344-5. View

13.

Croswell J, Kramer B, Kreimer A, Prorok P, Xu J, Baker S . Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009; 7(3):212-22. PMC: 2682972. DOI: 10.1370/afm.942. View

14.

Kappen S, Jurgens V, Freitag M, Winter A . Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey. Front Oncol. 2021; 11:691197. PMC: 8213068. DOI: 10.3389/fonc.2021.691197. View